12, 2010. The two public meetings held in 2009 and prior specific requests for comments focused on how FDA can improve its disclosure to the public. The Task Force soon plans to issue draft proposals related to those issues for public comment. This document focuses on the third phase of the transparency initiative.

# **II. Scope of the Meeting**

The Task Force is collecting information on how to improve FDA's transparency to regulated industry. It held three listening sessions with members of regulated industry on January 21, 27, and 28, 2010. FDA is making available transcripts and summaries of those listening sessions (see section IV of this document), and seeks public comment related to the issues raised in those sessions or other suggestions related to FDA's transparency to regulated industry. FDA is particularly interested in comments on how FDA can make improvements in the following areas:

1. Training and education for regulated industry about the FDA regulatory process in general and/or about specific new requirements.

2. The guidance development process.

3. Maintaining open channels of communication with industry routinely and during crises.

4. Providing useful and timely answers to industry questions about specific regulatory issues.

5. Communicating with sponsors during review of applications.

#### **III. Request for Comments**

Interested persons may submit to the Division of Dockets Management (see ADDRESSES) electronic or written electronic comments regarding this document. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. To permit time for interested persons to submit data, information, or views on this subject, submit comments by (see DATES). Where relevant, you should annotate and organize your comments to identify the specific question addressed by the question number referenced in the previous text. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management (see ADDRESSES) between 9 a.m. and 4 p.m., Monday through Friday.

### **IV. Transcripts**

Transcripts and summaries are accessible at *http://www.regulations.gov* 

and on the Transparency Task Force Web site at *http://www.fda.gov/ transparency.* Transcripts and summaries may be viewed at the Division of Dockets Management (see **ADDRESSES**). They will also be available in either hardcopy or on CD–ROM, after submission of a Freedom of Information request. Written requests are to be sent to Division of Freedom of Information (HFI–35), Office of Management Programs, Food and Drug Administration, 5600 Fishers Lane, rm. 6–30, Rockville, MD 20857.

Dated: March 5, 2010.

#### Leslie Kux,

Acting Assistant Commissioner for Policy. [FR Doc. 2010–5377 Filed 3–11–10; 8:45 am] BILLING CODE 4160–01–S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

### National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Cancer Institute Director's Consumer Liaison Group.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* National Cancer Institute Director's Consumer Liaison Group.

*Date:* March 24–26, 2010. *Time:* March 24, 2010, 2 p.m. to 6 p.m.

Agenda: Welcome, Overview of the Cancer Genome Atlas, Expert Panel on the Cancer Genome Atlas.

*Place:* National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892.

*Time:* March 25, 2010, 8:30 a.m. to 5:30 p.m.

*Agenda:* Report of the DCLG Genomics Working Group, Report on NCI Professional Judgment Budget, Board Discussion about Communicating with the Community about Genomics Research.

*Place:* National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892.

*Time:* March 26, 2010, 8:30 a.m. to 1 p.m. *Agenda:* Board Discussion about Engaging the Community around Genomics Research, Discussion with NCI Director.

*Place:* National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892.

*Contact Person:* Benjamin Carollo, MPA, Advocacy Relations Manager, Office of Advocacy Relations, Building 31, Room 10A30, 31 Center Drive, MSC 2580, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892–2580. 301–496–0307. *CAROLLOB@MAIL.NIH.GOV.* 

Information is also available on the Institute's/Center's home page: http:// deainfo.nci.nih.gov/advisory/dclg/dclg.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: February 26, 2010.

## Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy. [FR Doc. 2010–5454 Filed 3–11–10; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

# Center For Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Cancer

Diagnostics and Therapeutics SBIR/STTR. *Date:* March 18, 2010.

*Time:* 2 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Lambratu Rahman, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6214, MSC 7804, Bethesda, MD 20892, 301–451– 3493, rahmanl@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing